STOCKHOLM, October 13, 2010 /PRNewswire/ -- Pharmalink AB, a privately
held Swedish pharmaceutical company, has received orphan drug designation by
the US Food and Drug Administration (FDA) for its product candidate Nefecon
(PL-56) for patients with IgA nephropathy, also referred to as Berger's